UGT2B15 single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans
BackgroundDabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly UGT2B15, has not been extensively explored in human...
Saved in:
Main Authors: | Jin-Woo Park, Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Sungwook Yu, Ji-Young Park |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1507915/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dabigatran-induced Vasculitis on the Palms: A Case Report and Review of Literature
by: Snehal Balvant Lunge, et al.
Published: (2025-01-01) -
Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review
by: Tatyana S. Degtyareva, et al.
Published: (2024-12-01) -
Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment
by: N. S. Lapina, et al.
Published: (2020-07-01) -
Targeting UGT2B15 and NR1H4 interaction: a novel therapeutic strategy for polycystic ovary syndrome using naftopidil enantiomers
by: Xiufen Zheng, et al.
Published: (2025-01-01) -
UGT2B17基因的缺失多态性与鼻咽癌危险性的关系
Published: (2008-01-01)